VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
AMSTERDAM & BOSTON--(BUSINESS WIRE)--May 27, 2025--
VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527171431/en/
Jessica Atkinson, New CBO at VectorY Therapeutics
Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors.
'I'm delighted to welcome Jessica to VectorY,' said Jim Scibetta, chief executive officer of VectorY Therapeutics. 'Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team.'
'VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases,' said Atkinson. 'I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success.'
Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient.
About VectorY
VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see www.vectorytx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527171431/en/
CONTACT: VectorY Therapeutics B.V.
E-mail:[email protected]
Tel: +31 20 226 8020
Vigo Consulting (Media)
Melanie Toyne-Sewell / Rozi Morris
E-mail:[email protected]
Tel: +44 207 390 0237 / +44 20 7390 0231
KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE NEUROLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: VectorY Therapeutics
Copyright Business Wire 2025.
PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
http://www.businesswire.com/news/home/20250527171431/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Naps associated with increased risk of death, report says
June 5 (UPI) -- An afternoon snooze might seem appealing to middle-aged folks and seniors, but these naps could carry a high cost. People with certain types of napping patterns have a greater risk of an early death, researchers are slated to report at an upcoming meeting of the American Academy of Sleep Medicine. "People who slept longer during the day, had irregular daytime sleep patterns, or slept more around midday and early afternoon were at greater risk, even after accounting for health and lifestyle factors," lead researcher Chenlu Gao, a postdoctoral research fellow at Massachusetts General Hospital in Boston, said in a news release. The findings call into question the whole concept of the "power nap." For the study, researchers analyzed data on more than 86,500 people participating in the UK Biobank long-term health research project. These folks had their sleep habits monitored for a week using wrist devices, and researchers compared those habits to death records. Their average age was 63 at the time their napping was tracked. Nearly 5,200 people died during a follow-up of 11 years, researchers said. Results showed an increased risk of premature death for: • People who tended to take longer daytime naps • Folks whose napping patterns fluctuated frequently • People who napped between 11 a.m. and 3 p.m. This last observation contradicts academy guidelines, which encourages adults to limit themselves to "power naps" of no more than 20 to 30 minutes in the early afternoon, researchers noted. Naps that last longer than a half-hour can cause grogginess that undercuts the potential helpfulness of a siesta, researchers said. "Interestingly, the data that shows risks associated with napping around midday and early afternoon contradicts what we currently know about napping, so further research on that link could be warranted," Gao said. Gao is to present these findings Wednesday during the AASM's annual meeting in Seattle. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. More information The Mayo Clinic has more on napping for healthy adults. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
an hour ago
- Yahoo
Red Sox 'Do Not Want to Sell' at Trade Deadline According to MLB Insider
Red Sox 'Do Not Want to Sell' at Trade Deadline According to MLB Insider originally appeared on Athlon Sports. After a lackluster start to the 2025 season, the Boston Red Sox are in 'sellers' territory. Sitting at 30-34, the Red Sox are in danger of falling out of the postseason race. If they do, they would have plenty of players drawing interest in the trade market. Advertisement MLB insider for the New York Post, Jon Heyman, went on MLB Network and painted the picture for the Red Sox amid the trade deadline speculation. Heyman reported that the Red Sox, while having solid trade pieces, do not want to sell. "They've got some pieces as well," Heyman said. "But as I said, even a few games under .500, they do not want to sell." The Red Sox not wanting to be sellers isn't a surprise, as it would indicate that the team is out of contention for the postseason. Missing the postseason again could also cause Red Sox manager Alex Cora to lose his job. So, with Cora's job on the line and a postseason berth still within reach, the Red Sox do not want to be sellers. Advertisement However, in a situation where they do end up becoming sellers, they would have plenty of assets available. "There would be big interest in Jarren Duran if they do decide to sell," Heyman added. "I'm not saying it's likely they'll sell, but if they do, it should be a very good sale." Tim Heitman-Imagn Images Heyman continued talking about some of the options for the Red Sox to sell, including two pitchers on one-year deals. "Walker Buehler, very solid pitcher on a one-year deal," said Heyman. "Another guy on a one-year deal, Aroldis Chapman, 1.80 ERA, he's having a big year. He's hit 103 miles an hour." Both Chapman and Buehler could be moved if the Red Sox fall out of the postseason race. They'd have plenty of teams lining up for those two players, and it'd be an even longer line for Duran. Advertisement While the Red Sox don't plan to be sellers and hope to rebound and make a postseason push, the options on the roster if they do sell are great. Duran, Buehler, and Chapman would all be highly coveted. If the Red Sox do become sellers, while the Red Sox fandom would be disappointed, they would likely net a solid return on a few of their players in the trade market. Related: Red Sox Exec Breaks Silence Amid Alex Cora Hot Seat Rumors Related: Alex Cora Provides Lackluster Roman Anthony Red Sox Update This story was originally reported by Athlon Sports on Jun 6, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Why Nebius Group N.V. (NBIS) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Nebius Group N.V. (NASDAQ:NBIS) stands against other best-performing stocks on Thursday. Nebius Group grew its share prices by 17.54 percent on Thursday to close at $46.30 apiece after raising as much as $1 billion through the issuance of convertible notes. In a statement, Nebius Group N.V. (NASDAQ:NBIS) said that the funds will be raised in two tranches, the first of which amounts to $500,000 covering 2 percent convertible notes due 2029, while the remaining $500,000 will cover 3 percent convertible notes due 2031. A close-up of a businesswoman using a laptop, being illuminated by the AI-enabled cloud interface sponsored by the company. 'The fresh capital we are raising now gives us more firepower to go faster, paving the way for increased revenue opportunities in 2026 and further accelerating us toward our medium-term target of mid-single-digit billions of dollars in revenue as a high-margin business, with potential upside,' said Nebius Group N.V. (NASDAQ:NBIS) founder and CEO Arkady Volozh. 'Building foundational AI infrastructure is a capital-intensive business. In addition to access to the capital markets, we are fortunate to have non-core assets and equity stakes with significant growth profiles that can be used to support the future funding requirements of our core business,' he added. Overall, NBIS ranks 1st on our list of best-performing stocks on Thursday. While we acknowledge the potential of NBIS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
